近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）收到 国家药品监督管理局下发的多库酯钠《化学原料药上市申请批准通知书》。现将相 关情况公告如下： 一、《化学原料药上市申请批准通知书》主要内容 申请事项：境内生产化学原料药上市申请 化学原料药名称：多库酯钠 证券代码：003020 证券简称：立方制药 公告编号：2025-042 合肥立方制药股份有限公司 关于收到原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、多库酯钠的相关情况 多库酯钠是一种阴离子表面活性剂，通过物理性润滑肠道排便，其制剂多库酯 钠片用于慢性功能性便秘。截至本公告日，国家药品监督管理局药品审评中心原料 药登记数据显示，包括公司在内，仅有3家企业原料药登记状态为"A"（已批准在 上市制剂使用的原料），该品种进口原料药登记状态为"I"（尚未通过与制剂共同 审评审批的原料）。 三、对公司的影响及风险提示 多库酯钠原料药上市申请获得批准，将进一步丰富公司原料药产品管线，提升 公司市场竞争力。由于产品的生产和销售可能受到政策和市场等因素影响，仍具有 一定 ...

Core Viewpoint - The article discusses the rising trend of using "smart drugs" in high-pressure industries like finance and technology, highlighting both the demand for these drugs and the associated risks of misuse and legal issues [1][2][3]. Group 1: Market Demand and Supply - The first domestic "smart drug" was launched in April, leading to a surge in stock prices for the producing company, Lifan Pharmaceutical, which experienced five consecutive trading limit increases [1][14]. - The global ADHD drug market is projected to reach $14.71 billion by 2025, with a compound annual growth rate of 4.11%, indicating significant market potential for similar drugs [15]. - The only officially approved "smart drug" in China, "Zhuanzhu Da," has faced supply shortages due to high demand and limited production capacity, leading to difficulties for legitimate ADHD patients in obtaining the medication [10][12]. Group 2: Misuse and Legal Issues - Many individuals, particularly young professionals and students, are resorting to illegal means to obtain "smart drugs" like Adderall and Ritalin, often through online channels or underground networks [5][6][7]. - Reports indicate that a significant portion of users are motivated by academic pressures, with some even resorting to virtual currencies for cross-border purchases [6][7]. - The misuse of these drugs can lead to severe health risks, including addiction and various psychological and physical side effects, yet the allure of enhanced focus drives many to overlook these dangers [9][17]. Group 3: Industry Response and Future Outlook - Lifan Pharmaceutical's recent approval of a generic version of "smart drugs" is seen as a response to the supply-demand imbalance in the market, potentially alleviating some of the shortages faced by patients [16][17]. - The company plans to shift packaging operations to its domestic facility to increase supply efficiency, although challenges remain in meeting the high demand [13][17]. - The overall market for "smart drugs" is expected to grow, but the actual therapeutic benefits and risks associated with misuse continue to be a concern for healthcare professionals [17][18].

证券代码：003020 证券简称：立方制药 公告编号：2025-041 合肥立方制药股份有限公司 2024年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 1、公司于2025年5月12日召开2024年年度股东大会，审议通过了《2024年度利 润分配预案》。公司2024年度权益分派方案为：以公司当前总股本191,260,500股为 基数，向全体股东每10股派发现金人民币3.00元（含税），共计派发现金股利为 57,378,150.00元（含税）。本次利润分配不送红股，不以资本公积转增股本。 2、自上述权益分派方案披露至实施期间，公司股本总额未发生变化。 3、公司本次实施的权益分派方案与公司2024年年度股东大会审议通过的分配方 案及其调整原则一致。 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个月。 二、本次实施的利润分配方案 本公司2024年度权益分派方案为：以公司现有总股本191,260,500股为基数，向 全体股东每10股派3.000000元人民币现金（含税；扣税后，境外机构（含QFII、 RQFII）以及持有首发前限售股 ...

Core Viewpoint - The article discusses the rising trend of using "smart drugs" in high-pressure industries like finance and technology, highlighting both the demand for these drugs and the associated risks of misuse and legal issues [1][2][3]. Group 1: Market Dynamics - The first domestic "smart drug" was launched in April, leading to a surge in stock prices for the company, Lifan Pharmaceutical, which experienced five consecutive trading limit increases [2][37]. - The global ADHD medication market is projected to reach $14.71 billion by 2025, with a compound annual growth rate of 4.11%, potentially reaching $21.14 billion by 2034 [35]. - The only officially approved "smart drug" in China, "Zhuanzhu Da," has faced supply shortages due to high demand and limited production capacity [27][30]. Group 2: Usage and Misuse - "Smart drugs" are primarily used by individuals seeking to enhance focus and productivity, often leading to illegal procurement methods and health risks [6][10][12]. - Reports indicate that a significant number of young professionals and students are using these drugs to cope with academic and work pressures, with some resorting to illegal channels for acquisition [15][16][23]. - The misuse of these drugs can lead to addiction and various health issues, including anxiety, depression, and cardiovascular problems [19][46]. Group 3: Regulatory and Ethical Concerns - The strict regulation of "smart drugs" in China limits access for legitimate ADHD patients, creating a paradox where those in need cannot obtain the medication [23][24]. - The article highlights the ethical dilemma surrounding the use of "smart drugs," as they do not genuinely enhance cognitive abilities but merely increase focus temporarily [45].

Group 1 - Longjiang Transportation plans to reduce its shareholding by no more than 3% of the company's total shares, amounting to 39.4764 million shares, from June 4, 2025, to September 3, 2025 [1] - Shuangyi Technology intends to acquire 100% equity of Marky Industries Pty Ltd and specific assets for approximately AUD 18 million [1] - Haikong Air Conditioning's controlling shareholder has received a bank loan commitment of up to CNY 32 million for share repurchase [2] Group 2 - Zhaowei Electromechanical's shareholder plans to reduce its stake by no more than 1.50%, equating to 3.6031 million shares, from June 5, 2025, to September 4, 2025 [2] - Zhongwen Online's directors and senior management plan to collectively reduce their holdings by no more than 877,100 shares, representing 0.1203% of the total shares [2] - Liding Optoelectronics' shareholders plan to reduce their holdings by no more than 3%, totaling 12.2113 million shares, from June 5, 2025, to September 4, 2025 [4] Group 3 - Luvi Optoelectronics' shareholder plans to reduce its stake by no more than 1%, amounting to 1.9333 million shares, from June 4, 2025, to September 4, 2025 [5] - Jiejia Weichuang's controlling shareholder and concerted parties plan to reduce their holdings by no more than 0.72%, totaling 250,000 shares [7] - Yancoal Energy will no longer acquire control of Highfield Resources due to a new investment from Qinghai Salt Lake Industry Co., Ltd. [9] Group 4 - Yongdong Co., Ltd. plans to reduce its shareholding by no more than 1.26%, equating to 473,380 shares, from June 5, 2025, to September 4, 2025 [11] - Sanqi Interactive Entertainment plans to distribute a cash dividend of CNY 2.10 per 10 shares [12] - Salt Lake Co., Ltd. intends to acquire Highfield Resources for approximately USD 300 million to become its largest shareholder [13] Group 5 - Hainan Haiyao's shareholder plans to reduce its stake by no more than 3%, totaling 38.921 million shares, within 90 days after the announcement [14] - Lifang Pharmaceutical plans to transfer 2.2184% equity of Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for CNY 22.1837 million [16] - Zhiyou Technology's shareholders plan to reduce their holdings by no more than 2.99%, totaling 11.9986 million shares, from June 4, 2025, to September 3, 2025 [18] Group 6 - Puli Tui has applied for a review of the Shenzhen Stock Exchange's decision to terminate its listing [19] - Saimo Intelligent's shareholder plans to reduce its stake by no more than 3%, equating to 16.0659 million shares, from June 4, 2025, to September 3, 2025 [20] - Entropy Technology is planning to acquire 55% equity of Longzhiyuan to gain control [21] Group 7 - Nanjing Chemical Fiber plans to acquire 100% of Nanjing Process Equipment Manufacturing Co., Ltd. through asset swaps and cash payments [22] - Beijing Lier intends to invest CNY 200 million in Shanghai Zhenliang Intelligent Technology Co., Ltd. [23]

Group 1 - The company held its 21st meeting of the 5th Board of Directors on May 12, 2025, with all 7 directors present, confirming compliance with legal and regulatory requirements [1][2] - The Board approved the transfer of 2.2184% equity in Nanjing Mainowei Pharmaceutical Technology Co., Ltd. to Chengdu Yuanhe Yuandian Venture Capital Partnership (Limited Partnership) for a price of RMB 22.183748 million [1][2] - The company conducted a thorough review of the financial and credit status of the counterparty, concluding that they possess sufficient performance capability, and the risk of recovering the payment is controllable [2] Group 2 - The chairman of the company, Ji Junqiu, was authorized to negotiate the specific terms of the equity transfer and sign the relevant documents [2] - The resolution was passed with unanimous support, receiving 7 votes in favor, with no votes against or abstentions [2] - The decision was also reviewed and approved by the Board's Strategic Committee [2]

Transaction Overview - Hefei Lifan Pharmaceutical Co., Ltd. plans to transfer 2.2184% equity in Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for a price of 22.183748 million RMB [1] - The company currently holds 6.4984% equity in Mainowei, which will decrease to 4.2800% after the transfer [1] - The transfer does not constitute a related party transaction or a major asset restructuring as per regulations [1] Counterparty Information - The buyer, Chengdu Yuanheyuandian Venture Capital Partnership, is a limited partnership established on November 6, 2023, with a registered capital of 1.961 billion RMB [2] - The main shareholders include several venture capital firms, with no significant conflicts of interest identified [2] Target Company Information - Nanjing Mainowei Pharmaceutical Technology Co., Ltd. was established on February 7, 2021, with a registered capital of 5.256734 million RMB [4] - The company reported total assets of 11.36144 million RMB and net assets of 8.73122 million RMB as of December 31, 2024 [4] - Mainowei's business includes the production of medical devices and pharmaceuticals, with recent financials showing a net loss of 3.12407 million RMB for the first quarter of 2025 [4] Agreement Details - The equity transfer agreement stipulates a payment structure where 50% of the transfer price is paid upfront and the remaining 50% within 15 working days after the first payment [5] - The agreement includes various conditions that must be met before the transfer is finalized, including due diligence and legal compliance [6][7] Impact on Company - The transaction is expected to generate a pre-tax profit of approximately 17.9876 million RMB, impacting the company's financials for 2025 [10] - The board believes the transaction is fair and will not adversely affect the company's operations or shareholder interests [10]

证券代码：003020 证券简称：立方制药 公告编号：2025-038 合肥立方制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下简称"公司"）于2025年4月18日召开的 第五届董事会第二十次会议和第五届监事会第十八次会议及2025年5月12日召开 的2024年年度股东大会，审议通过了《关于回购注销部分限制性股票及调整回购 价格的议案》及《关于变更公司注册资本并修订〈公司章程〉的议案》。鉴于公 司2022年限制性股票激励计划存在部分激励对象离职已不符合激励对象条件，及 的相关规定，公司拟对首次授予及预留授予中尚未解除限售的全部限制性股票共 计1,078,318股进行回购注销。具体内容详见公司刊载于《证券时报》和巨潮资讯 网（http://www.cninfo.com.cn）的《关于回购注销部分限制性股票及调整回购价 格的公告》（公告编号：2025-025）、《关于变更公司注册资本并修订〈公司章 程〉的公告》（公告编号：2025-026）。本次限制性股票回购注销完成后，将导 致公司股份总数减少1,078,318股， ...

证券代码：003020 证券简称：立方制药 公告编号：2025-037 （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为：2025 年 投票系统投票的时间为：2025 年 5 月 12 日 9:15-15:00。 一、会议召开和出席情况 （1）现场会议时间：2025 年 5 月 12 日（星期一）下午 14:30。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 律法规、规范性文件和《公司章程》等规定。 （1）总体出席情况 通过现场和网络投票的股东及股东代理人 142 名，代表股份 116,932,031 股， 占公司有表决权股份总数的 61.1376%。 其中：通过现场投票的股东及股东代理人 23 名（代表 24 名股东），代表股 份 110,199,502 股，占公司有表决权股份总数的 57.6175%。通过网络投票的股东 | 序 | 审议 | 议案名称 | 表决 | 占出席会议有效表 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

证券代码：003020 证券简称：立方制药 公告编号：2025-039 特别提示： 1、本次交易存在可能终止的风险，敬请广大投资者注意投资风险。 一、交易概述 南京迈诺威医药科技有限公司（以下简称"迈诺威"）是合肥立方制药股份 有限公司（以下简称"公司"或"立方制药"）的参股公司，截至目前公司持有 迈诺威 6.4984%的股权。 因公司计划回收投资成本，拟转让部分迈诺威的股权，具体如下： | 序号 | 受让方 | 拟转让出资额 | 拟转让股权 | 拟转让价格 | | --- | --- | --- | --- | --- | | | | （万元） | 比例（%） | （万元） | | 1 | 成都元禾原点创业投 资合伙企业（有限合 | 11.6614 | 2.2184 | 2,218.3748 | | | 伙） | | | | | 合计 | -- | 11.6614 | 2.2184 | 2,218.3748 | 上述股权转让不构成关联交易、不构成《上市公司重大资产重组管理办法》 规定的重大资产重组事项。 合肥立方制药股份有限公司 关于转让参股公司部分股权的公告 本公司及董事会全体成员保证信息披露的内容真实、 ...